Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
TAK · against 1,336 other Healthcare companies
Ranked #743 of 1,337 · scores higher than 44% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 40–49, including TAK · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | TAK | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | Not reported | 1.5% | — | — | 30% |
| EBITDA yieldHigher is better · 1,357 reported | 8.0% | 4.2% | 74% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 4.6% | -1.0% | 77% | 20% | |
| Book yieldHigher is better · 1,306 reported | 71.0% | 37.9% | 76% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 743 | 871.6B INR (≈$10.5B) | 44 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 66 |
| 743 | 5.7B USD | 44 | 38 |
| 743 | 182.3B INR (≈$2.2B) | 44 | 66 |
| 743 | 1.3B USD | 44 | 58 |
| 743 | 66.3B USD | 44 | 30 |
| 743 | 5.9B USD | 44 | 39 |
| 756 | 6.7B CNY (≈$938M) | 43 | 30 |
| 756 | 1.62T KRW (≈$1.2B) | 43 | 50 |
| 756 | 2.9B HKD (≈$366M) | 43 | 47 |